A prospective, multi-centre, double-blind, randomized, study to evaluate the safety and efficacy of Saroglitazar 4mg versus Placebo in the treatment of HIV associated lipodystrophy. - PRESS IX

Trial Profile

A prospective, multi-centre, double-blind, randomized, study to evaluate the safety and efficacy of Saroglitazar 4mg versus Placebo in the treatment of HIV associated lipodystrophy. - PRESS IX

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Saroglitazar (Primary)
  • Indications HIV-associated lipodystrophy syndrome
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 27 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top